Article Details
Retrieved on: 2025-03-13 20:04:20
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses aTyr Pharma's progress in developing efzofitimod, a treatment for lung disorders like pulmonary sarcoidosis and systemic sclerosis-related interstitial lung disease. This ties into biopharma by showcasing innovation in disease-modifying therapies targeting inflammation. Tags specify the focus on lung disorders and the company's involvement.
Article found on: www.globenewswire.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here